Dana-Farber/Harvard Cancer Center (DF/HCC) Sponsored Funding
A. David Mazzone Research Awards Program
High Impact Trial Award
Sponsor: Non-Federal (DFCI)
Award Amount: Up to $250,000 per year for two years for direct costs only ($500,000 total).
One page Letter of Intent due by February 28, 2013. Submit letter online: Application Form Web Page
Application deadline: 04:59:59 PM EST, Friday, April 5, 2013
Funding decisions will be made through peer review by June 15, 2013
Anticipated award date: August 1, 2013
Submission requirements: Applications must be submitted online: Application Form Web Page
Applications submitted using other means will not be reviewed or considered for this award. Applicants should notify their grant administrator/office and follow their institutionís policies and procedures for approval to submit applications. Applications will not be accepted after 04:59:59 PM EST, Friday, April 5, 2013.
Please direct questions to:
Juan Carlos Hincapie
Tel: (617) 632-6155
The A. David Mazzone Research Awards Program funds a series of collaborative and innovative cancer research, career development, community outreach, and training projects to address a range of needs in prostate cancer and Lupron-treatable diseases.
High Impact Trial Awards are large-scale, prostate cancer research projects for multi-institutional teams of investigators (at least four institutions). This award is designed to harness medical discoveries to test new compounds and therapies which inhibit putative targets and to study responses and prolongation of survival in Castration Resistant Prostate Cancer (CRPC). The award seeks to study why and how response or resistance reflects the degree of drug-target interaction. These projects should expand the focus of prostate cancer clinical trials from traditional outcome measures, such as early changes in PSA to time-to-event end points, which capture the impact of treatment. Projects may focus on clinical manifestations in phase II trials to screen or select promising therapies. Research should involve novel therapeutics in efforts to understand mechanisms of activity or resistance of agents and should have a high probability of near-term patient benefit. In addition, the grant is intended to result in multi-year, peer-reviewed funding. These grants will be awarded to multi-institutional teams of investigators who have at least one DF/HCC member as a principal investigator. Mazzone Program funding will support only the scientific aspects of the clinical trial such as pharmacodynamic endpoints and biomarkers. Traditional trial conduct costs should be supported by other funding mechanisms.
One award for $250,000 per year for up to two years ($500,000 total in direct costs) is available in this category. The next projected award period is August 1, 2013 to July 31, 2015. One award remains in this category to be awarded over a two-year period
Funding Agency: The funding agency for the program is a grant from the U.S. District Court for the District of Massachusetts. Funding was derived from a pool of unclaimed funds from the settlement in 2004 of a class action suit against TAP Pharmaceuticals. The class action suit was related to marketing and sales practices for the prostate cancer drug Lupron.
The Mazzone Awards Program is a non-federal DFCI sponsored award, administered jointly through DF/HCC and the Prostate Cancer Foundation.
Applications will be accepted from two or more independent investigators, at least one of whom holds a full-time Harvard faculty appointment at the level of Assistant Professor or higher, and is a DF/HCC member. Applicants from institutions throughout the country are encouraged to apply as long as they have a collaborator in one of the DF/HCC institutions. Applications including investigators from more than one DF/HCC member institution are encouraged. The intent is to foster high-impact collaborative research. Applicants may apply for multiple grants; however, individuals may only be awarded one A. David Mazzone Research Award at a time.
Employees or subcontractors of a government entity or for-profit private industry are not eligible. Exceptions include applicants holding full-time positions at a veterans' hospital or national laboratory (e.g., Lawrence Berkeley National Laboratory) in the United States. Members of the Programís Scientific Advisory Board (SAB) are ineligible to apply.
PROPOSAL SUBMISSION INFORMATION
Required items (4):
- Application Form: To be completed online by the Principal Investigator when submitting your proposal to the Application Form Web Page. Provide a 250-word abstract description of the project in laymenís terms.
- Research Proposal: The proposal should describe the research to which this award would be applied if funded. Maximum of 5 pages of text including figures. References and budget pages are not included in this page limit. Appendix material will be accepted with the following restrictions: a two-page limit of relevant supporting text or figures; only manuscripts that have been accepted for publication with the journal acceptance letter.
- Biosketches: Current NIH Biosketch for each participating PI, including all funding sources.
- Budget: Budget requests (direct costs only) and budget justifications should be submitted as NIH 398 form with major divisions of funds (personnel, equipment, supplies, other, etc.; with adequate rationale). Separate budget pages must be submitted for each individual institution requesting funds. Funds will be distributed directly from DFCI to sub-recipients. A composite budget that includes the total costs of the project should also be included when multiple institutions are involved in the project. PIs may include a level of effort and salary support commensurate with their efforts on the project. Support and effort may be split between the collaborating PIs. Funds may be used for direct research expenses only, which may include salary and benefits of PIs, postdoctoral or clinical research fellows and/or research assistants, research/laboratory supplies, and equipment.
- IRB approval if applicable will be required prior to funding.
Format: Items 2 Ė 4 (above) must be compiled and submitted as a single PDF file. Please include the PIís name, project title, and page number at the top of each page.
Submit Proposal Online: Application Form Web Page
Application Deadline: 04:59:59 PM EST, Friday, April 5, 2013.
IN FAIRNESS TO ALL THERE WILL BE NO EXCEPTIONS TO THIS DEADLINE
Applications will be reviewed by members of the Programís Scientific Review Board. Grants will be awarded on the basis of the following review criteria (in order of importance):
- Significance. The project should address an important problem or a critical barrier to progress in the field. The aims of the project should advance scientific knowledge, technical capability, and/or clinical practice and have near-term patient impact.
- Inter-institutional links. Proposals that foster inter-institutional research will be favored.
- Investigators. The PIs, collaborators, and other researchers should have the necessary experience, expertise, and proven track records of accomplishment. The investigators should have complementary and integrated expertise.
- Innovation. The application should challenge and seek to shift current research or clinical practice paradigms by utilizing novel theoretical concepts, approaches or methodologies, instrumentation, or interventions.
- Approach. The overall strategy, methodology, and analyses should be well-reasoned and appropriate to accomplish the specific aims of the project.
- Environment. The scientific environment in which the work will be done should contribute to the probability of success.
- Potential to gain independent funding. There should be a high likelihood that project will lead to NCI or other cancer research foundation funding.
Grantees must submit annual progress reports to DF/HCC including detailed narrative updates, accrual reports (if applicable), and expenditure reports. Progress will be measured through the review of progress reports, by the publication of research in academic journals, and if relevant, by progress in clinical trial activity. Generally, progress that approximately meets benchmarks, timelines, or specific aims that are set forth within corresponding proposals will be funded on a per-year basis through the completion of the grant term. Unanticipated scientific findings that delay research timelines will not exclude grantees from continued funding so long as grantee research is of a high-caliber and within the scope of the original research proposal.